Therapeutic Goods Amendment Regulations 2000 (No. 5)

Overview

The Therapeutic Goods Amendment Regulations 2000 (No. 5), issued under the authority of the Parliamentary Secretary to the Minister for Health and Aged Care, aim to amend the Therapeutic Goods Act 1989 by introducing regulations for the manufacture of fresh blood and blood components. The Act itself was enacted to establish a national system of controls for the quality, safety, efficacy, and timely availability of therapeutic goods used or exported from Australia. These amendments respond to the need for a national regulatory system to address the increasingly sophisticated manufacturing procedures for fresh blood and blood components, as recommended by a working party formed by the Australian Health Ministers' Advisory Council. By removing the exemption for these products and limiting future exemptions to emergency situations, the amendments seek to ensure compliance with national standards for their manufacture. The Therapeutic Goods Administration is responsible for administering the Act and these regulations, which commence on the date of gazettal. The amendments to the Therapeutic Goods Regulations 1990 include updating the reference to the Red Cross to the "Australian Red Cross Blood Service" and modifying the exemption criteria for fresh blood and blood components. Specifically, the exemption will only apply to blood collected or manufactured by medical practitioners for the direct treatment of their patients or by blood donation centres for the treatment of patients under the care of specific medical practitioners. This regulatory change aligns Australia's approach to the oversight of fresh blood and blood components with that of other countries, ensuring the safety and efficacy of these critical therapeutic goods.

Scope and Application

The Therapeutic Goods Amendment Regulations 2000 (No. 5) pertains to the regulation of therapeutic goods within Australia, specifically targeting the manufacture of fresh blood and blood components. The Act applies to entities involved in the manufacture of therapeutic goods, with a particular focus on blood and blood components, and encompasses both private and public sector entities such as the Australian Red Cross Blood Service. These regulations extend nationally, as the Act is administered under Commonwealth jurisdiction through the Therapeutic Goods Administration (TGA). The Regulations aim to ensure the quality, safety, efficacy, and timely availability of therapeutic goods by imposing a licensing regime for the manufacture of these goods. However, certain exemptions apply, such as for blood and blood components collected or manufactured by medical practitioners in specific circumstances, and those collected or manufactured by blood donation centres for direct patient treatment. The Regulations are effective from 1 July 2000, as stipulated in the Schedule, and the amendments are designed to align Australian practices with international standards by imposing stricter controls on the manufacture of fresh blood and blood components.

Key Provisions

The Therapeutic Goods Amendment Regulations 2000 (No. 5) (the Regulations) introduce changes to the Therapeutic Goods Regulations 1990 (the original Regulations) to amend the licensing requirements for the manufacture of fresh blood and blood components. Regulation 3 of the Regulations provides that these amendments apply to the Therapeutic Goods Regulations 1990 as detailed in Schedule 1. The amendments aim to bring fresh blood and blood components under a regulated licensing regime, aligning Australia with international practices where these products are subject to stringent regulatory controls. Under the original Regulations, the manufacture of fresh blood and blood components was exempt from the licensing requirements set out in Part 4 of the Therapeutic Goods Act 1989 (the Act). However, the new Regulations, as detailed in Item 2 of Schedule 1, limit this exemption to specific circumstances. Specifically, the exemption applies only to blood and blood components collected by a medical practitioner in the course of medical treatment for diagnosis and testing purposes, or manufactured by a medical practitioner or under their supervision for a specific patient under their direct care. Additionally, the exemption applies to blood and blood components manufactured by a blood donation centre for a specific patient under the care of a medical practitioner. This change reflects the advanced technology and specialised processes involved in the manufacture of these products, ensuring that national standards apply to their production. Entities and individuals involved in the manufacture of fresh blood and blood components must comply with the licensing requirements set out in Part 4 of the Act unless they fall under one of the limited exemptions outlined in the Regulations. This includes obtaining the necessary licences to engage in any step of the manufacture of these products. The Therapeutic Goods Administration (TGA) is responsible for administering these licensing requirements and ensuring compliance with the Act and the Regulations. Failure to comply with the licensing requirements for the manufacture of fresh blood and blood components may result in civil or criminal penalties. Under the Act, individuals or entities that engage in the manufacture of therapeutic goods without the required licence may be subject to fines and other penalties. The specific penalties for breaches of the Act and Regulations are not detailed in the provided Explanatory Statement but would typically include fines and potential imprisonment for serious or repeated breaches. Compliance with the new Regulations is crucial to ensure the safety and quality of fresh blood and blood components in Australia.